Biotech Values

[iwfal]

It does come back to the idea that Rib's synergistic effect is mainly due to shifting Th2 to Th1. Indeed, given Lambda itself can shift the axis towards Th1, Rib might be redundant in reducing viral load. I do agree monotherapy will likely get beaten by relapse,

Confused. If Rib's primary benefit does come from shifting towards Th1, and Ifn-L does the same thing why wouldn't that also benefit decreased relapses?

I truly do think it likely that the ph ii is going to have to have three arms: standard treatment, a monotherapy lambda arm and a rib/lambda combo - to assess precisely such things as relapse rate.